Gopro Inc. (GPRO) 63.95 $GPRO Jim Cramer's 'Mad Money'

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gopro Inc. (GPRO) 63.95 $GPRO

Jim Cramer's 'Mad Money' Recap: Six Winning Earnings Themes
at The Street - 4 mins ago
Cramer says that down days show investors who's swimming and who's just treading water.
AMBA: 122.99 (+0.49), FIT: 46.20 (+0.67), AMZN: 482.18 (-6.09), GPRO: 63.95 (+2.27), SWKS: 103.12 (+3.48), FBHS: 47.07 (+2.89), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), RTN: 103.21 (+6.22), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), GOOGL: 674.73 (-20.37), OC: 44.27 (-1.35), FTNT: 46.83 (+4.53)

This Is Not the Time to Go Skinny Dipping
at The Street - Thu Jul 23, 1:16PM CDT
When tide goes out, smart stocks are wearing Speedos.
FIT: 46.20 (+0.67), AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), LMT: 202.83 (+0.04), HD: 114.59 (-0.31), FEYE: 48.73 (+2.11), CYBR: 61.72 (+4.22), NKE: 114.00 (-0.09), FBHS: 47.07 (+2.89), UTX: 101.14 (-0.41), NOC: 165.50 (-0.78), VFC: 74.67 (+0.50), PANW: 197.09 (+4.69), UA: 95.93 (+6.56), WHR: 179.43 (+1.07), FTNT: 46.83 (+4.53)

Stocks Mixed Near Midday; GoPro Aims Higher
at Investor's Business Daily - Thu Jul 23, 11:09AM CDT
Stocks were narrowly mixed near Thursday's halftime amid a swarm of earnings reports and some better-than-expected economic reports. The Nasdaq rose 0.2%, but it was up as much as 0.5% intraday. Chips, fiber optics and security software issues...
GPRO: 63.95 (+2.27), VRX: 253.84 (+14.92), CAT: 76.88 (-2.88), INFN: 23.15 (+1.86)

Jim Cramer: GoPro (GPRO) Stock Is a 'Bargain at These Levels'
at The Street - Thu Jul 23, 10:29AM CDT
GoPro (GPRO) stock is trading in the green after Jim Cramer explained why he thinks it's a bargain at these levels on CNBC's Mad Money show Wednesday night.
GPRO: 63.95 (+2.27)

The Trader Daily: Don't Get Caught Up in Everything That Could Go Wrong
at The Street - Thu Jul 23, 6:00AM CDT
Try to follow a basic, easy-to-understand model.
JNK: 37.82 (+0.02), GPRO: 63.95 (+2.27), HYG: 87.50 (-0.05), SPY: 210.18 (-1.19), MSFT: 46.11 (+0.57), TLT: 121.09 (+1.49), AAPL: 125.16 (-0.06)

Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella
at The Street - Thu Jul 23, 5:00AM CDT
Cramer says Fitbit, Ambarella and GoPro may not be too expensive to own with their growth rates and market potential.
FIT: 46.20 (+0.67), AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), ONCE: 69.77 (+2.62), LYV: 26.19 (-0.07)

Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls
at The Street - Wed Jul 22, 7:42PM CDT
Cramer is not worried about Apple, and suggests viewers sit back and wait until the post-earnings panic subsides.
AMBA: 122.99 (+0.49), FIT: 46.20 (+0.67), GPRO: 63.95 (+2.27), KNDI: 7.57 (-0.04), GE: 26.26 (-0.37), KR: 38.67 (-0.34), UTX: 101.14 (-0.41), EXAS: 25.05 (-0.24), LYV: 26.19 (-0.07), MUR: 34.51 (-0.13), TXMD: 8.50 (+0.28), ONCE: 69.77 (+2.62), FOXA: 33.23 (-0.46), BEAV: 48.34 (+0.86), DPZ: 111.65 (-0.66), GOOGL: 674.73 (-20.37), AAPL: 125.16 (-0.06)

Bears: The Gang That Couldn't Shoot Straight
at The Street - Wed Jul 22, 3:10PM CDT
They have the ammunition but they keep misfiring in the market.
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), EGRX: 94.17 (+0.76), NFLX: 110.10 (-1.40), ISRG: 557.20 (+7.32), YHOO: 39.21 (-0.03), BIDU: 207.63 (+1.89), SPY: 210.18 (-1.19), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)

Apple's Fall Takes a Big Bite Out of Market Indexes
at The Street - Wed Jul 22, 3:08PM CDT
Apple's tumble pressured markets on Wednesday, punishing benchmark indexes in a post-earnings slump.
GPRO: 63.95 (+2.27), BRCM: 52.30 (+0.54), FB: 95.44 (-1.60), HAL: 42.33 (+0.79), BA: 146.11 (-0.36), NFLX: 110.10 (-1.40), YHOO: 39.21 (-0.03), LNKD: 224.10 (-0.70), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), STJ: 75.53 (-1.14), XLK: 42.59 (-0.09), THOR: 63.06 (-0.40), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), BHI: 59.26 (+0.98)

Cramer -- 'Don't Not Own Apple,' but Wait a Bit to Buy Facebook
at The Street - Wed Jul 22, 2:13PM CDT
With Apple trading lower following its latest quarterly results, many Twitter questioners wanted Jim Cramer's views about whether stock in the world's largest-cap company is a buy, sell or hold.
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), CYBR: 61.72 (+4.22), FB: 95.44 (-1.60), AKAM: 73.51 (+0.76), C: 59.87 (-0.47), BAC: 18.18 (-0.27), TWTR: 36.19 (+0.10), PANW: 197.09 (+4.69), AAPL: 125.16 (-0.06)

Stocks Slip as Crude Oil Settles Below $50
at The Street - Wed Jul 22, 1:57PM CDT
Stocks remain in the red on Wednesday as crude oil closes below $50, its lowest level since April 2.
GPRO: 63.95 (+2.27), BRCM: 52.30 (+0.54), FB: 95.44 (-1.60), HAL: 42.33 (+0.79), BA: 146.11 (-0.36), NFLX: 110.10 (-1.40), YHOO: 39.21 (-0.03), LNKD: 224.10 (-0.70), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), STJ: 75.53 (-1.14), XLK: 42.59 (-0.09), THOR: 63.06 (-0.40), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06), BHI: 59.26 (+0.98)

Bull Chart of the Day: GoPro
at The Street - Wed Jul 22, 1:01PM CDT
When a stock drops after solid earnings, it can present a nice setup. Is GoPro one of those?
GPRO: 63.95 (+2.27), CMG: 725.94 (+0.12)

5 Things to Know About Ambarella - Stocks in the News
Madeleine Johnson - Zacks Investment Research - Wed Jul 22, 12:14PM CDT
Here's a look at investor favorite Ambarella Inc, a video-processing and chip-maker company that has taken Wall Street by storm.
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), GOOGL: 674.73 (-20.37), GOOG: 644.28 (-17.82)

You're Missing Your Chance, Bears
at The Street - Wed Jul 22, 11:52AM CDT
There's not much market movement right now.
ISRG: 557.20 (+7.32), NFLX: 110.10 (-1.40), TSLA: 267.20 (-0.67), AMZN: 482.18 (-6.09), GPRO: 63.95 (+2.27), YHOO: 39.21 (-0.03), SPY: 210.18 (-1.19), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)

GoPro (GPRO) Stock is the 'Chart of the Day'
at The Street - Wed Jul 22, 11:06AM CDT
GoPro (GPRO) stock is the subject of today's Trifecta Stocks 'Chart of the Day' analysis.
GPRO: 63.95 (+2.27)

Thank Goodness for the Dip Buyers
at The Street - Wed Jul 22, 10:30AM CDT
Market's doing a good job of ignoring Apple earnings.
ISRG: 557.20 (+7.32), NFLX: 110.10 (-1.40), TSLA: 267.20 (-0.67), AMZN: 482.18 (-6.09), GPRO: 63.95 (+2.27), YHOO: 39.21 (-0.03), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)

GoPro Q2 Earnings Zoom on Rising Products Popularity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 10:20AM CDT
Leading portable video camera maker GoPro, Inc. (GPRO) reported second-quarter 2015 non-GAAP earnings per share of 35 cents, which came over 300% higher than the year-ago quarter figure of 8 cents.
GPRO: 63.95 (+2.27), ACIW: 23.43 (-0.56), TM: 133.25 (-0.74), AAPL: 125.16 (-0.06)

GoPro Set for Meteoric Rise
at The Street - Wed Jul 22, 10:00AM CDT
GoPro is breaking out this week on good turnover, and momentum is bullish after yesterday's earnings beat.
GPRO: 63.95 (+2.27)

Stocks Fall Back as Crude Oil Dips Below $50
at The Street - Wed Jul 22, 9:53AM CDT
Stocks return to near session lows on Wednesday morning as crude oil dips below $50 a barrel on the back of a rise in weekly inventories.
KO: 40.84 (-0.06), GPRO: 63.95 (+2.27), BA: 146.11 (-0.36), T: 33.93 (-0.34), YHOO: 39.21 (-0.03), CMG: 725.94 (+0.12), DTV: 92.19 (-0.64), STJ: 75.53 (-1.14), THOR: 63.06 (-0.40), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading